Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Canada / NCT05995769
Recruiting Phase 2

Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder

NCT05995769 · tracked via the Priya Life Science Canada tracker
Sponsor
University of Calgary
Phase
Phase 2
Started
2024-03-20
Last updated
2024-05-07

Condition(s) studied

Alcohol Use DisorderAlcoholism

Investigational drug(s) / intervention(s)

Psilocybin →

Psilocybin: Single dosing session followed by 5 MET weekly sessions starting 24hrs after dosing

Study summary

The aim of this study is to determine if a single dose of psilocybin administered with motivational enhancement therapy (MET) can reduce heavy drinking in patients with an alcohol use disorder (AUD).

Eligibility

Sex
ALL
Min age
22 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Meets DSM-5 AUD criteria of at least moderate severity * Meets heavy drinking requirements (heavy drinking days, number of drinks) in past 30 days * Desire to decrease alcohol consumption * Limited lifetime hallucinogen use Exclusion Criteria: * Severe or moderate substance use disorder other than alcohol or nicotine in past 6 months * Diagnosis of schizophrenia, bipolar disorders or first-degree relative with diagnosis * Active suicidal ideation or serious attempt within past 3 years * Currently pregnant, nursing, or trying to become pregnant * Any notable abnormality on ECG, physical exam, or routine medical blood laboratory test

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
University of Calgary Calgary Alberta Recruiting

More University of Calgary trials in Canada

Virtual Self-Management Program for JIA Recruiting
Rapid, Accurate, Cost-effective Assessment of Blood Biomarkers for Diagnosis of Concussion Recruiting
The Need for Repeat ERCP After Endoscopic Treatment of Postsurgical Biliary Leaks Active, not recruiting
Evaluation of Foreign Body Airway Obstruction Interventions: A Prospective Cohort Study of Adults and Children Recruiting
Fecal Immunochemical Test for Post-polypectomy Surveillance to Reduce Unnecessary eNdoscopy Recruiting

Other trials for the same condition

Evaluating Cannabidiol as a Novel Anticraving Medication for Alcohol Use Disorder Active, not recruiting
Effects of Action-Based Cognitive Remediation on Substance Misuse in Early Phase Psychosis Recruiting
Piloting of an Intervention to Reduce Problematic Alcohol Use in Early Phase Psychosis Patients Recruiting
Phenotyping Patients With Alcohol and Cannabis Use Disorders Using the Addictions Neuroclinical Assessment Recruiting
ACT_for Alcohol Use Disorder and Depression Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05995769 on ClinicalTrials.gov ↗ ← All trials in Canada